Oral immunotherapy: treating an allergy with the thing that causes it
One of the strangest-sounding treatments in medicine is oral immunotherapy, usually abbreviated to OIT.
The basic principle is to give carefully controlled amounts of the allergenic food and gradually increase exposure under a specialist protocol.
In other words:
Treat the allergy by repeatedly giving the allergen.
That sounds like the opposite of everything we have said about avoidance.
The crucial difference is control.
OIT does not mean taking a mustard-allergic child home and adding progressively larger quantities of mustard to dinner.
Clinical immunotherapy uses defined doses, specialist assessment, escalation protocols and monitoring because allergic reactions can occur during treatment.
The intention is to alter the immune response sufficiently that a larger dose can be tolerated.
For peanut allergy, oral immunotherapy now has a substantial clinical evidence base. European guidance recommends peanut OIT for children and adolescents and suggests OIT for some children with persistent milk or egg allergy.
But notice the missing word.
Mustard.
Current major European guidelines do not recommend routine mustard oral immunotherapy because the necessary mustard-specific clinical evidence simply isn't there.
Could the same principle eventually work for mustard?
Biologically, there is no obvious reason to declare mustard permanently outside the field of allergen immunotherapy.
But "scientifically plausible" and "proven treatment" are very different standards.
To establish mustard OIT properly, researchers would need to answer questions such as:
What mustard preparation should be used?
How much mustard protein is actually in each dose?
What starting dose is appropriate?
How quickly should it increase?
How often do reactions occur during treatment?
Which patients are suitable?
What maintenance dose is required?
How long must treatment continue?
What happens if doses are missed?
Does protection persist after treatment stops?
Does treatment improve quality of life enough to justify its risks and inconvenience?
For peanut, researchers have spent years investigating questions like these.
For mustard, we do not have anything approaching the same evidence base.
So for now:
Mustard immunotherapy is an interesting possibility, not a routine treatment somebody should expect from an allergy clinic.
A patch instead of a mouthful
Oral immunotherapy is not the only way scientists have tried to teach the immune system to respond differently to food.
Another approach is epicutaneous immunotherapy.
"Epicutaneous" essentially means through the skin.
A patch containing a controlled amount of allergen is applied to the skin, allowing allergen exposure through that route.
Researchers have investigated this particularly for peanut allergy.
The concept is attractive because the amount of allergen entering the body can be very small, potentially producing a different balance between effectiveness and treatment reactions from swallowing allergen.
European guidance regards epicutaneous immunotherapy as a potential option for peanut allergy based on the evidence, although availability at routine point of care remains limited.
Again, this is not currently established mustard treatment.
It is important because it demonstrates that scientists are exploring several ways of modifying the allergic immune response rather than assuming the only possible intervention is lifelong avoidance.
Under the tongue: another route to the immune system
There is also sublingual immunotherapy, or SLIT.
"Sublingual" means under the tongue.
Small amounts of allergen are placed there rather than swallowed as a conventional food dose.
The tissues of the mouth contain immune cells capable of interacting with the allergen.
Sublingual immunotherapy has been investigated for food allergies including peanut and is also familiar from treatment of some respiratory allergies.
As with epicutaneous treatment, the attraction is partly that the route and dose may offer a different balance between immune training and adverse reactions.
But again, the important EatSafe distinction is:
Promising food-allergy technology is not automatically proven mustard-allergy treatment.
Then came a completely different idea
Allergen immunotherapy tries to change the immune response by repeatedly exposing the patient to the allergen.
Another strategy asks:
What if we interfere with the allergic machinery itself?
Remember IgE.
It is the antibody sitting at the centre of many immediate food-allergic reactions.
A medicine called omalizumab targets IgE.
It is a monoclonal antibody — essentially a laboratory-manufactured antibody designed to recognise a particular biological target.
Its target is IgE.
You can think of omalizumab as intercepting much of the free IgE before that IgE can arm the immune cells involved in allergic reactions.
That analogy is simplified, but it captures the central idea.
Instead of teaching the immune system separately about peanut, milk, egg, mustard and every other allergen, perhaps we can turn down part of the common IgE machinery they use.
That possibility has produced one of the biggest developments in food-allergy treatment in recent years.
The OUtMATCH trial changed the conversation
In the US OUtMATCH trial, researchers studied people with multiple food allergies.
Participants had peanut allergy plus allergies to at least two other specified foods.
After treatment with omalizumab, researchers challenged them with the foods under controlled conditions.
The results were striking.
About 67% of participants receiving omalizumab were able to consume a single dose of at least 600 mg of peanut protein without dose-limiting symptoms, compared with about 7% receiving placebo.
Treatment also significantly increased thresholds for several of the other foods studied.
That led the US Food and Drug Administration in 2024 to approve omalizumab for certain adults and children aged one year and older with IgE-mediated food allergy, to reduce allergic reactions — including the risk of anaphylaxis — following accidental exposure to one or more foods.
That sentence contains an extremely important phrase:
accidental exposure.
Omalizumab does not mean "eat whatever you like"
The FDA explicitly states that people taking omalizumab for food allergy must continue avoiding the foods to which they are allergic.
It is not an emergency treatment for anaphylaxis.
It does not replace adrenaline.
And it does not make every treated person completely unreactive.
Indeed, the FDA's detailed review showed substantial variation between patients. Some people still reacted at relatively low challenge doses despite treatment.
So this isn't a force field.
It is better understood as potentially raising the threshold at which accidental exposure produces a reaction.
Again, the concept of a safety margin becomes important.
But was mustard actually tested?
No — not in the pivotal OUtMATCH group of foods on which these headline results are based.
The trial investigated peanut and specified foods including cashew, milk, egg, walnut, wheat and hazelnut.
So it would be wrong for EatSafe UK to write:
"Omalizumab has been shown to protect people with mustard allergy."
That specific claim has not been established by this trial.
What we can say is more interesting and more accurate.
Omalizumab targets IgE biology rather than one particular food protein, and European food-allergy guidance now suggests omalizumab as an option for IgE-mediated food allergy in children from age one and in adults.
That raises the possibility that biologic approaches may eventually benefit people with less common IgE-mediated allergies that would never individually attract the enormous clinical-trial programmes devoted to peanut.
But the evidence for any particular patient and allergen still matters.
A mechanism is not a substitute for a clinical trial.
This could matter enormously for rarer allergies
There is an economic problem hidden inside allergy research.
Suppose millions of people have Allergy A.
Pharmaceutical companies and research organisations have a large population in which to test treatments.
Now suppose comparatively few people have Allergy B.
Running an enormous treatment programme specifically for Allergy B becomes much harder.
Mustard is closer to the second situation, particularly in Britain.
A treatment aimed at a shared part of the allergic pathway, rather than one individual food, could therefore be particularly important for people with rarer allergies.
It offers the possibility that they may benefit from advances in allergy medicine without waiting for a mustard-specific pharmaceutical industry to emerge.
That is not a promise.
It is a genuinely important direction of travel.
What would a real cure look like?
The word cure deserves a much higher bar than it often receives in headlines.
Suppose a treatment means somebody can tolerate mustard while taking medication every fortnight.
That's valuable.
But stop the medicine and the protection disappears.
Is that a cure?
Probably not in the ordinary meaning of the word.
Suppose oral immunotherapy allows somebody to tolerate mustard provided they eat a maintenance dose every day.
Again, potentially life-changing.
But if six months without treatment restores the allergy, we are dealing primarily with maintained desensitisation.
A compelling definition of a true cure would be something closer to:
The person can stop treatment, encounter a normal amount of the food months or years later, and remain tolerant without needing continuing therapy.
That is a much harder biological achievement.
It requires the immune system not merely to be temporarily restrained, but to develop durable tolerance.
Scientists are trying to understand what tolerance actually is
For decades, allergy medicine largely described outcomes.
React.
Don't react.
Now researchers increasingly want to understand the cellular machinery underneath those outcomes.
What happens to allergen-specific IgE?
What happens to other antibody classes such as IgG4?
What happens to mast cells and basophils?
What happens to regulatory T cells — immune cells involved in controlling immune responses?
Which molecular signatures distinguish temporary desensitisation from durable tolerance?
Can we identify the people most likely to respond before treatment begins?
Can biologic drugs make immunotherapy safer?
Can several interventions be combined?
The eventual future of food-allergy treatment may therefore look less like one miraculous cure and more like precision immunology.
Different treatments for different biological patterns.
And perhaps one day "avoid it forever" will sound old-fashioned
It is worth appreciating how rapidly the field has already changed.
For much of modern allergy medicine, the fundamental management strategy for food allergy was:
Identify the food. Avoid the food. Carry emergency medication.
Those remain essential principles today.
But they are no longer the entire scientific horizon.
We now have allergen immunotherapy capable of increasing reaction thresholds for particular allergies.
We have biologic medicines capable of modifying the IgE pathway across multiple food allergies.
We have molecular diagnostics becoming increasingly sophisticated.
We have research into prevention before allergy develops.
The future may involve combinations of these approaches.
Mustard allergy has not yet received the treatment research attention enjoyed by peanut allergy.
But somebody diagnosed with mustard allergy today should not necessarily assume that the medical options available in 2040 will be identical to those available in 2026.
That is exactly why a living resource such as this needs to be reviewed rather than merely published.
But treatment isn't the whole burden of food allergy
There is another side of allergy that medical studies historically measured rather badly.
A person may avoid every reaction for an entire year and still have had a terrible year with their allergy.
They may have checked thousands of labels.
Turned down invitations.
Worried about restaurants.
Argued with people who thought they were being difficult.
Watched their child go to a birthday party without them.
Carried adrenaline everywhere.
Spent holidays translating menus.
Thrown away food after a recipe change.
Asked the same awkward question at every café.
And lived with the knowledge that one mistake could matter.
If researchers count only allergic reactions, that person appears to have had a successful year.
Clinically, perhaps they did.
Psychologically and socially, the story may be very different.
This is why modern allergy medicine increasingly recognises quality of life as an outcome worth measuring in its own right.
And mustard allergy has a peculiar psychological challenge.
It is uncommon enough that many people have barely heard of it.
Sometimes the allergic person therefore has to persuade other people that their allergy exists before they can even begin explaining how to accommodate it.